Wegovy vs Trulicity
A side-by-side look at Wegovy and Trulicity, two prescription medications advertised on TV. Informational only — not medical advice.
| US Wegovy | US Trulicity | |
|---|---|---|
| Generic name | semaglutide | dulaglutide |
| Drug class | GLP-1 Receptor Agonist | GLP-1 Receptor Agonist |
| Treats | Chronic weight management, cardiovascular risk reduction | Type 2 diabetes |
| Category | Weight Management | Diabetes |
| Manufacturer | Novo Nordisk | Eli Lilly |
| Year approved | 2021 | 2014 |
| FDA warning | Black box warning | Black box warning |
| Est. TV ad spend | $380M | $240M |
| Common side effects | Nausea, Diarrhea, Vomiting, Constipation | Nausea, Diarrhea, Vomiting, Abdominal pain |
Frequently asked questions
Is Wegovy or Trulicity better?
Neither is universally "better." Wegovy (semaglutide) is used for chronic weight management, cardiovascular risk reduction, while Trulicity (dulaglutide) is used for type 2 diabetes, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Wegovy and Trulicity?
Wegovy is a GLP-1 Receptor Agonist made by Novo Nordisk, while Trulicity is a GLP-1 Receptor Agonist made by Eli Lilly. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Wegovy has the larger estimated TV advertising budget of the two.